Extract
Arginine infusions (0.5 g/kg body wt) have been performed in low birth weight infants in order to study the insulin and glucagon control of the glucose homeostasis in the transient hypoglycemia of small for gestational age infants. To evaluate the glucose output by the liver, intramuscular glucagon injection (0.1 mg/kg body wt) was also effected. Twenty-six appropriate for gestational age infants (AGAI) and 29 small for gestational age infants (SGAI), 11 of which were affected by hypoglycemia during the first few days of life, were selected.
In the hypoglycemic SGAI the mean level of glucose in blood showed an evident decrease after arginine, the means being significantly lower at 30 (P < 0.001) and 60 (P < 0.001) min of the test than those of the AGAI and nonhypoglycemic SGAI. The mean levels of insulin in plasma of the nonhypoglycemic SGAI were significantly lower than those of the AGAI during the whole arginine test (P < 0.001 at 0 min, P < 0.05 at 30 min, P < 0.01 at 60 min); however, when the hypoglycemic SGAI were compared with the AGAI such differences no longer existed.
The mean levels of glucagon in plasma were high at fasting and showed a significant (P < 0.05) increase after the arginine infusion without any difference among the means of the three groups of infants at any time of the test. The mean insulin to glucagon molar ratio (ratio between the simultaneous molar concentrations of insulin and glucagon in plasma) was relatively reduced in comparison with the values reported in the adult and did not show any significant variation after arginine, nor was there any significant difference among the I I three groups of infants at any time of the test. After glucagon injection an increase of the blood glucose values was observed in AGAI and nonhypoglycemic SGAI, without any significant difference of the means. In the 1 I hypoglycemic SGAI the mean levels of glucose in blood throughout the test were lower than those of the other two groups of neonates, but their mean increase on the basal level did not differ significantly from that of the control subjects.
These results offer evidence to exclude an impairment of the modulation of the bihormonal pancreatic secretion as an important factor of the hypoglycemia of low birth weight infants and to confirm the inability of hepatic response to glycogenoly tic stimuli.
Speculation
During intravenous arginine infusion the mean values of the insulin to glucagon molar ratio in plasma of hypoglycemic SGAI infants did not differ significantly from those of control infants. The insulin to glucagon molar ratio could indicate, more than the examination of the single hormones, that in SGAI affected by transient hypoglycemia the deficiency of the glucose homeostasis is not correlated with an impairment of the endocrine pancreatic activity.
It is likely that the liver of such infants has a greater sensitivity t o glycogenosynthetic than t o glycogenolytic stimuli.
Several factors have been suggested as being a t the root of the transient hypoglycemia of SGAI. Shelley and Neligan (32) have reported a reduction of hepatic glycogen stores; liver size small relative t o that of brain has been found by Dawkins (9) in hypoglycemic infants who died; deficient hepatic neoglucogenesis from lipids and amino acids have been considered as other important factors in the pathogenesis of hypoglycemia (1 1.
Hormonal control of the glucose homeostasis in infants affected by this type of hypoglycemia has not been studied extensively. Human growth hormone secretion has been found t o be normal in three cases (19) ; deficient secretion of catecholamines was found by Stern et al. (33) , but not by others (3, 7, 24), and low cortisol production rate has been reported in some subjects (20) . However, such hormone secretion impairments are only occasional data and d o not seem t o play a significant role in the pathogenesis of the hypoglycemia of SGAI. High insulin concentrations have been found in the plasma of such infants a t fasting (10) and after glucose (22) or glucagon (23) injection, but their role in precipitating hypoglycemia is not yet well established.
Only recently glucagon has been assayed in plasma of the human neonate, but data concerning glucagon secretion in this form of neonatal hypoglycemia are not yet available.
In low birth weight infants arginine infusion has been performed t o investigate concomitantly insulin and glucagon secretion, and intramuscular glucagon injection t o estimate the increase of glucose in blood.
MATERIALS AND METHODS
A total of 55 infants were studied. All of them had a birth weight of less than 2,500 g. Their gestational age was calculated from the date of the first day of the last menstrual period. The gestational age was also assessed clinically according t o the criteria of Dubowitz et al. (10) . Twenty-six infants were considered t o be AGAI, their birth weight being above the 10th percentile, according to the intrauterine growth curves of Battaglia and Lubchenco (4) . The other 29 infants were considered t o be SGAI, their birth weight being below the 10th percentile. Infants born t o diabetic mothers, infants affected by erythroblastosis fetalis o r with congenital abnormalities, and infants presenting an Apgar score <7 were excluded from this research. Other information relative to these infants is reported in Table 1 .
Serial glucose estimations (using the Dextrostix test paper or a glucose oxidase method (18)) were performed from the 6th h r of life and during the first 5 or 6 days after birth. We considered an infant t o be hypoglycemic when levels of glucose in blood were found t o be lower than 20 mg/100 ml in a t least two determinations. Eleven cases of SGAI developed hypoglycemia and will be considered as a separate group. Since care was taken t o initiate treatment before symptoms arose, a distinction between symptomatic or asymptomatic hypoglycemia was not considered.
T o prevent hypoglycemic disturbances, six SGAI, who showed values for glucose in blood lower than 20 mg/100 ml before the arginine test, were slowly infused with glucose 5% at a rate of 20-25 ml/hr for 3-4 hr. This infusion was discontinued 2-3 h r before the test, which was performed when the levels of glucose in blood were relatively steady. This glucose infusion, which did not stimulate cells (16) , and during which levels of glucose in blood never exceeded 70 mg/100 ml, was performed also in 1 0 normoglycemic SGAI ; and in 8 AGAI as control subjects. The other five hypoglycemic SGAI developed hypoglycemia later, after the arginine test was concluded.
Arginine (35) of blood) and kept on ice. Whole blood was immediately precipitated and analyzed for glucose; the remaindero was centrifuged a t 4O and the plasma was stored a t -25 for analysis of insulin and glucagon.
I
An intramuscular injection of glucagon (34), in a dose of 100 /.lg/kg of body wt, was administered t o 3 4 infants (15 AGAI, 1 5 normoglycemic SGAI, and 9 hypoglycemic SGAI), 2-3 h r after the end of the arginine test, and blood glucose was assayed a t 0 , 3 0 , 60, and 9 0 min.
Glucose in blood was estimated by a , glucose oxidase , method ( I s ) , using reagents from Boerhinger Mannheim, G.m.b.H. Plasma insulin was measured by immunoassay method (17, 38) . Glucagon in plasma was measured by immunoassa (21) using a porcine glucagon standard (39) , porcine [''l]glucagon (40) , and the 3 0 K antiglucagon antiserum (41), which is highly specific for pancreatic I glucagon. All statistical calculations (42) were performed b y Student t test. Linear regression analysis was studied among the following data at fasting and throughout the arginine test: level of glucose in blood versus insulin and glucagon level versus insulin t o glucagon molar ratio; insulin level versus glucagon level; change in glucose in blood on the basal level versus insulin and glucagon change a t 3 0 and 6 0 min of the test.
Moreover, linear regression analysis was studied between the change in glucose in blood on the basal level after the arginine infusion and the glucose increase in blood on the basal level after the intramuscular glucagon injection. (Table 2) , the mean levels of glucose in blood of the AGAI showed a negligible increase, the variations ranging between -20 and 3 0 mg/100 ml. The concentration of insulin in plasma increased significantly (P 0.01) a t 3 0 rnin (Table 3) , the variations ranging between -3 and 22 yU/ml and the mean (+ 1 SD) change being 5.0 f 7.0 pU/ml. Also, the plasma glucagon concentrations showed, at 3 0 min, a significant (P 0.05) increase (Table 4) , the variations ranging between -33 and 825 pg/ml and the mean (f 1 SD) change being 159 f 245 pg/ml. The mean value of insulin t o glucagon molar ratio (Fig. 1 ) did not change significantly after the arginine infusion.
Normoglycemic SGAI. Also in this group of infants the levels of glucose in blood ,increased only slightly at the end of the arginine influsion (Table 2) , the variations ranging between -4 and 24 ma1100 ml. In comparison with the AGAI group, the normogly~emic SGAI showed a significantly higher increase at 3 0 (P 0.02) and at 6 0 (P 0.01) min. The mean level of insulin in plasma showed a significant (P 0.01) increase a t 3 0 rnin (Table 31 , which ranged between 1 and 13 yU/ml, the mean (f 1 SD) change being 6.3 f 3.4 pU/ml. The mean insulin concentrations in plasma of normoglycemic SGAI were significantly lower than those of the AGAI during the whole arginine test (0 min, P 0.001; 3 0 min, P 0.05; 6 0 min, P 0.01).
The mean glucagon levels in plasma showed a significant (P 0.05) increase a t the end of the arginine infusion (Table 41, 
Hypoglycemic SGAI. In the hypoglycemic group of SGAI an evident decrease of the glucose mean level in blood was observed after the arginine infusion, the difference being significant at 3 0 (P 0.001) and at 6 0 (P 0.001) rnin when the I mean values were compared with those of the other t w o groups of neonates. Such reduction in the level of glucose in blood was observed in 8 cases out of 11 of the hypoglycemic SGAI, whereas, i n the AGAI, it was present in 5 out of 26 and, in the normoglycemic SGAI, in 2 out of 18. The insulin concentrations in plasma increased significantly (P 0.05) a t 3 0 min, the variations ranging between -2 and 2 3 ~U / m l , and the mean change being 10.0 f 10.1 pU/ml. The mean insulin value in plasma at fasting of the hypoglycemic infants resulted in a value significantly higher than that of the normog1ycemic SGAI (P 0.05), but n o significant difference was observed when comparing hypoglycemic SGAI with AGAI. Also, in the hypoglycemic group, a significant increase of t h e glucagon concentrations in plasma was registered at 3 0 rnin (P 0.05), this increase ranging between 6 0 and 730 pg/ml and the mean ' AGAI: appropriate for gestational age infants; SGAI: small for gestational age infants.
change being 234 f 296 pg/ml. No difference of the mean values was found at any time of the test in the comparison with the other two groups of infants. The mean value of the insulin t o glucagon molar ratio did not change significantly after the. arginine infusion; it resulted in a value higher than that of the other two groups of neonates during the whole test, yet there was n o statistically significant difference.
INTRAMUSCULAR GLUCAGON INJECTION
The glycemic responses t o glucagon injected intramuscularly are reported in Table 5 . Although in the hypoglycemic SGAI the mean levels of glucose in blood resulted in values lower than those of the other two groups of infants throughout the test, the increase in mean level of glucose in blood in SGAI on the basal level did not differ significantly.
There was n o relation among individual blood glucose, plasma insulin, and glucagon levels and insulin t o glucagon ratio; neither was there any relation between findings resulting from the arginine test and the glucagon test. In particular, n o correlation was found between levels of insulin in plasma and concentrations of glucose in blood after arginine in the hypoglycemic SGAI. No significant difference was found within each of the three groups between infants receiving glucose and those not receiving it before the arginine and the glucagon test.
DISCUSSION
The glucose homeostasis instability of the SGAI in the immediate postnatal period has been displayed by the glycemic response t o arginine of the infants presenting hypoglycemia during the first days of life. In six of such infants levels of glucose in blood under 20 mg/100 ml were found before the tests were performed. Though slow glucose infusion allowed the hypoglycemic group t o have a basal mean level not significantly different from that of the control subjects at the time of the test, the arginine infusion caused a decrease of the mean glycemic values, with a pattern which resulted in values quite different from those registered for AGAI and for nonhypoglycemic SGAI. On the other hand, this glycemic response t o arginine of the hypoglycemic SGAI does not seem attributable t o the preceding glucose infusion, because n o difference was observed within the three groups between the infants who had and those who had not receivedglucose infusion.
The levels of insulin in plasma were found t o increase after arginine in the three groups of infants studied. The P cell sensitivity of the neonate t o arginine has already been reported (30, 3 1) . However, some differences in the concentration of insulin in plasma were observed in the comparison among the three groups of infants. The normoglycemic SGAI were found t o have, during the whole arginine test, levels of insulin in plasma significantly lower than those of the AGAI. However, when hypoglycemic SGAI were compared with AGAI, s u c h , differences n o longer existed. Moreover, in the hypoglycemic group fasting levels of insulin in plasma were found t o be I significantly higher than those in the normoglycemic SGAI.
'
The glucagon concentrations in the plasma of the low birth weight infants of this study have been found t o b e relatively high in comparison with those of the adult. An increase of the levels of this hormone has been observed soon after birth (5, 25) . As reported elsewhere (12) , values have been found to ' increase after arginine, demonstrating that arginine is a stimulus t o glucagon secretion in the human neonate. This is in agreement with reports of arginine administration in the rat fetus and neonate (1 1, 15 ). There was n o difference among the mean values of the three groups of infants a t any time during the arginine test, nor was there any within the three groups I between infants who had or had not received glucose before the test.
These findings seem t o indicate that an impairment of the LY cell activity is not responsible for the hypoglycemia of the low birth weight infants. On the contrary, a relatively h'igh activity I of the fl cell might be at the basis of the pathogenesis of this pathologic condition. The low levels of insulin in plasma found ' in the normoglycemic SGAI seem t o suggest that in such infants the P cell function adapts itself t o the critical metabolic condition derived from intrauterine malnutrition; however, such adaptation does not seem t o take place in hypoglycemic SGAI.
However, n o correlation was registered between the blood glucose values and the insulin concentrations in plasma after arginine i n the hypoglycemic subjects. The Kt value of hypoglycemic SGAI was found by Le Dune (22) t o be high irrespective of whether they had normal or increased insulin secretion. Therefore, the abnormally increased p cell activity ' AGAI: appropriate for gestational age infants; SGAI: small for gestational age infants. ' AGAI: appropriate for gestational age infants; SGAI: small for gestational age infants.
may not be the most important factor responsible for the paradoxical blood glucose decrement determined in the hypoglycemic infants by arginine. Moreover, as insulin and glucagon oppose each other with respect to the glucose homeostasis, the insulin t o glucagon molar ratio, which is related to the concentrations of the two hormones, is considered to be a more reliable index of the pancreatic endocrine activity (34) . In the adult such molar ratio has been found to change in correlation with the several metabolic needs. During the arginine test in the normal adult (2), as well as in the older child (12) , an increase of the insulin to glucagon molar ratio has been described associated with an evident increase of the levels of glucose in blood. The values observed in the fasting low birth weight infants would favor glucose production by the liver; moreover, they did not change after the arginine infusion, which indicates an equimolar increase of the two hormones without any significant difference between the hypoglycemic SGAI and the other infants. As a molecule of glucagon has been calculated to be at least threefold more efficacious than that of insulin, the glucose reduction in blood observed in the hypoglycemic infants does not appear to depend directly on an impairment of the endocrine pancreatic function.
The glucose increment in blood after arginine infusion has been interpreted as being caused by hepatic glycogenolysis stimulated by the glucagon secretion (13) . In fact, the physiologic increases in insulin concentrations have been found to inhibit glucagon-induced urea production but t o fail to inhibit glucagon-stimulated glycogenolysis (26) . Moreover, an increase of the turnover of glucose has been reported during the arginine test (34) . Such physiologic data might allow two interpretations for the abnormal glycemic response to arginine in the hypoglycemic SGAI.
A deficiency of hepatic glycogen stores have been incriminated as responsible for the hypoglycemia of SGAI (32) . In the cases studied in this report, the intramuscular glucagon injection has demonstrated that the glucose increment in blood on the basal level of the hypoglycemic SGAI did not differ from that of the other infants, although the mean values were significantly lower during the test. The effect on the levels of glucose in blood of the physiologic glucagon increases induced by arginine and that of the pharmacologic doses of this hormone during the glucagon test cannot be compared adequately. However, although the glycogen stores cannot be quantitatively valued by the rise in level of glucose in blood after glucagon, the results obtained in this research give cause to doubt the interpretation that the hepatic glycogen depletion is at the root of the reduction of glucose in blood during the arginine test.
The second hypothesis is that the tissues of hypoglycemic SGAI have an abnormally increased avidity for glucose. In SGAI affected by transient symptomatic hypoglycemia, an abnormal increase of the disposal of the glucose injected intravenously was reported by Gentz et al. (14) . It seems that some analogy exists between this finding and the paradoxical decline of the glycemic levels observed in the hypoglycemic SGAI after arginine, yet no distinction could be made as to whether they were affected by symptomatic or asymptomatic hypoglycemia. Nitzan and Groffman (29) reported that in the intrauterine growth retardation, experimentally induced in the rat, the incorporation of glucose into hepatic glycogen was twofold greater than in the normally developed rat fetus. Therefore, the glycemic pattern during the arginine test registered in the hypoglycemic SGAI might indicate that in intrauterine malnutrition the liver is more sensitive to factors stimulating glycogenosynthesis than to factors stimulating glycogc? ?olysis.
SUMMARY
Levels of glucose in blood, insulin in plasma, and glucagon response to arginine were studied during intravenous arginine infusion in 55 low birth weight infants, 26 AGAI, and 29 SGAI. Hypoglycemia was observed in 11 SGAI during the first few days of life. Intramuscular glucagon injections were also given in order to estimate the glucose output by the liver.
In the hypoglycemic SGAI a significant decrease of the mean level of glucose in blood was registered during the arginine test. Such glycemic decrease was not correlated with either a high level of insulin in plasma or low glucagon response to arginine in plasma. In fact, the mean values of the insulin to glucagon molar ratio did not change after the arginine administration and did not show any significant difference at any time of the test among the three groups of infants.
The mean increase of glucose in blood on the basal level registered after glucagon injection in the hypoglycemic SGAI did not differ significantly from that of the two other groups.
This might indicate that the blood glucose reduction after arginine infusion in the hypoglycemic SGAI is a consequence of a greater hepatic sensitivity to factors stimulating glycogenosynthesis than to factors stimulating glycogenolysis.
